Clinical Advantage Provisio Medical’s SLT IVUS technology offers real-time, automatic lumen measurements without iodinated contrast, presenting a compelling value proposition for vascular surgeons and interventional radiologists seeking safer and more accurate endovascular guidance.

Regulatory Milestone FDA 510(k) clearance for the SLT IVUS system established in April 2024 enables immediate market entry and deployment discussions with hospitals and imaging centers looking to adopt next-gen intravascular imaging.

Clinical Adoption Recent AMP conference activity and early clinical experience with critical limb-threatening ischemia provide a narrative for engaging wound care, vascular surgery, and limb salvage teams on early adopters and case studies.

Strategic Partnerships Physician Advisory Board and ongoing clinical collaborations suggest opportunities to co-develop payer-tailored evidence, training programs, and workflow integrations with endovascular device manufacturers and distributor networks.

SMB Growth Path With a lean team and revenue in the lower mid-market range, Provisio Medical is well positioned to pursue targeted hospital systems, regional health networks, and ambulatory surgery centers that are investing in advanced intravascular imaging to differentiate care and improve outcomes.